Pharma Mirror

APRIL 21, 2024

With the rapid development of biotechnology and molecular medicine, the introduction of mRNA as a vaccine or therapeutic agent enables the production of almost any desired functional protein/peptide within the human body.

In-Vitro 130

In-Vitro Drugs Genetic Disease RNA 130

Delveinsight

JANUARY 12, 2021

The companies believe that their candidate in its original IgG format has shown potent neutralization activity in in vitro assays and in an in vivo animal model. This will have an advantage over the multiple vaccines that have been getting EUA, which are not suitable for immunocompromised patients. and Europe.

Licensing 52

Licensing Licensing Antibody Gene Therapy 52

The Pharma Data

DECEMBER 20, 2020

Food and Drug Administration (FDA) is plenty busy with COVID-19 vaccine Emergency Use Authorizations (EUAs) this month, but they’re also wrapping up the year with a few PDUFA dates for other therapies. Here’s a look. Urovant Sciences’ Vibegron for Overactive Bladder. The drug is a once-daily, beta-3 adrenergic agonist.

In-Vitro 52

In-Vitro FDA Approval Manufacturing Licensing 52

Drug Discovery World

FEBRUARY 28, 2023

mRNA technology helped us to vaccinate the world against SARS-CoV-2. Approximately 7,000 rare and ultra-rare diseases have been described, and yet, 90% have no approved therapeutic options 1. And while these conditions are rare, the patients and families affected are many.

Genetics 52

Genetics Genetic Analysis Vaccination Vaccine 52

Drug Discovery World

FEBRUARY 22, 2024

Dementia is the only major cause of death without a treatment to prevent, slow or stop disease progression. “In With the breadth and range of central nervous system disorders – for example Parkinson’s disease and multiple sclerosis – facing the global population there is an unmet need within this area of drug discovery.

Drugs 59

Drugs Gene Clinical Trials Clinical Trials 59